Hjem › Nyrekreft (nyrecellekarcinom) › Minnesota
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Minnesota
20 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i Minnesota.
Byer i Minnesota
- Rochester14 studier
- Minneapolis7 studier
- Saint Paul7 studier
- Bloomington6 studier
- Plymouth5 studier
- Brooklyn Park4 studier
- Duluth4 studier
Offisiell studietekst (engelsk)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Mayo Clinic Rochester, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07419841A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- HealthPartners Cancer Research Center, Saint Paul
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- og 48 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #68, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- Fairview Southdale Hospital, Edina
- og 8 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Rochester, Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04981119Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Minnesota Oncology and Hematology PA, Minneapolis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology Hematology PA-Chaska, Chaska
- og 17 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Minnesota Oncology Hematology, P.A., Burnsville
- Minnesota Oncology Hematology, P.A., Chaska
- Minnesota Oncology Hematology, P.A., Coon Rapids
- og 6 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07227415ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- og 18 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06661720A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Metro-Minnesota Community Clinical Oncology ( Site 0144), Saint Louis Park
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT07227402Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 3. aug. 2026 · NCT05433142A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2026 · NCT03972657KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Mayo Clinic Comprehensive Cancer Center, Rochester
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. jun. 2026 · NCT06026410VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Mayo Clinic in Rochester, Rochester
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. jun. 2026 · NCT07510334Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Rochester, Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 12. mar. 2026 · NCT06349642A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT06682793Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Mercy Hospital, Coon Rapids
- og 21 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04510597A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Mayo Clinic in Minnesota, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. nov. 2024 · NCT05824975Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.